总市值

Search documents
安杰思收盘上涨2.13%,滚动市盈率22.19倍,总市值65.86亿元
Sou Hu Cai Jing· 2025-08-04 12:05
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjiasi Medical Technology Co., Ltd., which operates in the medical device industry, specifically focusing on minimally invasive diagnostic and therapeutic instruments [1][2] - As of August 4, Anjiasi's stock closed at 81.33 yuan, reflecting a 2.13% increase, with a rolling price-to-earnings (PE) ratio of 22.19 times and a total market capitalization of 6.586 billion yuan [1] - The average PE ratio for the medical device industry is 54.32 times, with a median of 38.11 times, positioning Anjiasi at the 48th rank within the industry [1][2] Group 2 - As of July 31, 2025, Anjiasi has 5,365 shareholders, an increase of 202 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company specializes in the research, production, and sales of endoscopic minimally invasive diagnostic and therapeutic instruments, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - In the latest quarterly report for Q1 2025, Anjiasi reported a revenue of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.248 million yuan, reflecting a year-on-year growth of 6.57%, with a gross profit margin of 70.68% [1]
振德医疗收盘上涨1.04%,滚动市盈率16.46倍,总市值59.74亿元
Sou Hu Cai Jing· 2025-08-04 11:17
振德医疗用品股份有限公司的主营业务是医疗和健康产品的研发、生产与销售。公司的主要产品是基础 护理、手术感控、压力治疗与固定、造口及现代伤口护理、感控防护。公司曾先后获得包括省级重点企 业研究院、省级工程技术研究中心、省级高新技术企业研究中心、省级企业技术中心、省创新型试点企 业、省级专利示范企业在内的多项技术奖项,并通过国家高新技术企业评审。 8月4日,振德医疗今日收盘22.42元,上涨1.04%,滚动市盈率PE(当前股价与前四季度每股收益总和的 比值)达到16.46倍,创145天以来新低,总市值59.74亿元。 从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均54.32倍,行业中值38.11倍,振德医疗排 名第36位。 截至2025年一季报,共有3家机构持仓振德医疗,其中基金3家,合计持股数145.13万股,持股市值0.31 亿元。 来源:金融界 最新一期业绩显示,2025年一季报,公司实现营业收入9.92亿元,同比2.87%;净利润5124.19万元,同 比-30.19%,销售毛利率34.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5振德医疗16.4615.511.0559.74 ...
乐普医疗收盘上涨3.00%,滚动市盈率211.49倍,总市值303.72亿元
Sou Hu Cai Jing· 2025-08-04 10:07
8月4日,乐普医疗今日收盘16.15元,上涨3.00%,滚动市盈率PE(当前股价与前四季度每股收益总和的 比值)达到211.49倍,创279天以来新低,总市值303.72亿元。 从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均54.32倍,行业中值38.11倍,乐普医疗排 名第113位。 乐普(北京)医疗器械股份有限公司的主营业务是医疗器械、药品、医疗服务及健康管理。公司的主要产 品是医疗器械、药品、医疗服务及健康管理。 最新一期业绩显示,2025年一季报,公司实现营业收入17.36亿元,同比-9.67%;净利润3.79亿元,同 比-21.44%,销售毛利率64.03%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13乐普医疗211.49122.991.97303.72亿行业平均 54.3250.504.72116.17亿行业中值38.1137.682.7056.52亿1九安医疗10.9911.120.87185.49亿2新华医疗 15.9814.821.30102.47亿3英科医疗16.0817.331.43254.01亿4山东药玻16.1016.151.85152.30亿5振德医疗 16 ...
澳洋健康收盘上涨3.41%,滚动市盈率114.91倍,总市值32.54亿元
Sou Hu Cai Jing· 2025-08-04 08:38
Core Viewpoint - On August 4, Aoyang Health's stock closed at 4.25 yuan, up 3.41%, with a rolling PE ratio of 114.91, marking a new low in 35 days, and a total market capitalization of 3.254 billion yuan [1] Company Summary - Aoyang Health's main business includes medical services, pharmaceutical distribution, and biotechnology, with key products being medical services and pharmaceutical logistics [1] - The company has received several honors, including third place in the 7th National Hospital Quality Circle Competition and recognition as a demonstration hospital for improving medical services [1] - Aoyang Hospital has signed a contract with the China Trauma Rescue Alliance to enhance its trauma rescue capabilities, significantly reducing mortality and disability rates among severely injured patients [1] - The company ranked 32nd in the non-public hospital top 100 list published by the Alipay Hospital Management Research Center and is second among county-level non-public hospitals nationwide [1] Industry Summary - The average PE ratio for the medical services industry is 47.79, with a median of 59.03, placing Aoyang Health at 39th in the industry ranking [2] - The latest quarterly report for Q1 2025 shows Aoyang Health achieved revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82%, with a gross profit margin of 15.09% [2] - Comparatively, the industry average PE (TTM) is 47.79, while Aoyang Health's PE (TTM) stands at 114.91, indicating a significant premium over the industry average [2]
弘业期货收盘上涨1.43%,滚动市盈率275.06倍,总市值121.84亿元
Jin Rong Jie· 2025-08-04 08:33
Group 1 - The core viewpoint of the article highlights the performance and valuation of Hongye Futures, which has a current stock price of 12.09 yuan, a PE ratio of 275.06, and a total market capitalization of 12.184 billion yuan [1][2] - Hongye Futures operates in the diversified financial industry, which has an average PE ratio of 70.96 and a median of 29.30, placing Hongye Futures at the 20th position in the industry ranking [1][2] - As of January 10, 2025, Hongye Futures has 40,409 shareholders, a decrease of 517 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - The main business activities of Hongye Futures include commodity futures brokerage, financial futures brokerage, futures investment consulting, asset management, and fund sales [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 643 million yuan, a year-on-year increase of 259.09%, and a net profit of 1.2032 million yuan, up 109.07% year-on-year [1]
爱博医疗收盘下跌1.82%,滚动市盈率38.74倍,总市值146.44亿元
Sou Hu Cai Jing· 2025-08-04 05:52
Company Overview - Aibo Medical closed at 75.72 yuan on August 1, with a decline of 1.82%, resulting in a rolling PE ratio of 38.74 times and a total market capitalization of 14.644 billion yuan [1] - The company ranks 80th in the medical device industry, which has an average PE ratio of 53.65 times and a median of 37.22 times [1] Shareholder Information - As of March 31, 2025, Aibo Medical had 9,729 shareholders, a decrease of 94 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Aibo Medical focuses on the independent research, production, sales, and related services of ophthalmic medical devices, with key products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] Financial Performance - In the latest quarterly report for Q1 2025, Aibo Medical reported revenue of 357 million yuan, a year-on-year increase of 15.07%, while net profit was 92.5581 million yuan, reflecting a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]
维力医疗收盘上涨1.51%,滚动市盈率17.69倍,总市值41.47亿元
Sou Hu Cai Jing· 2025-08-03 05:42
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Weili Medical, indicating a steady growth in revenue and profit, alongside a relatively low PE ratio compared to the industry average [1][2] - As of August 1, Weili Medical's stock closed at 14.16 yuan, with a PE ratio of 17.69 times and a total market capitalization of 4.147 billion yuan [1] - The medical device industry has an average PE ratio of 53.65 times, with Weili Medical ranking 40th among its peers [1][2] Group 2 - For the first half of 2025, Weili Medical reported a revenue of 745 million yuan, representing a year-on-year increase of 10.19%, and a net profit of 121 million yuan, up 14.17% year-on-year [1] - The company's gross profit margin stands at 45.04%, indicating a strong profitability in its operations [1] - The company specializes in the research, production, and sales of medical catheters in various fields, including anesthesia, urology, respiratory care, and hemodialysis [1]
中国石化收盘下跌5.32%,滚动市盈率15.24倍,总市值6898.85亿元
Sou Hu Cai Jing· 2025-08-02 08:43
中国石油化工股份有限公司的主营业务为石油及天然气和化工业务。石油及天然气业务包括勘探、开发 及生产原油及天然气;管输原油、天然气;将原油提炼为石油制成品;以及营销原油、天然气和成品 油。化工业务包括制造及营销广泛的工业用化工产品。是中国大型油气生产商;炼油能力排名中国第一 位;在中国拥有完善的成品油销售网络,是中国最大的成品油供应商;乙烯生产能力排名中国第一位, 构建了比较完善的化工产品营销网络。 最新一期业绩显示,2025年一季报,公司实现营业收入7353.56亿元,同比-6.91%;净利润132.64亿元, 同比-27.60%,销售毛利率15.66%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5中国石化15.2413.710.836898.85亿行业平均 12.7711.481.201822.90亿行业中值30.5334.601.6461.42亿1中国海油9.158.941.5712329.27亿2中国石油 9.409.461.0015575.09亿3广汇能源12.1711.701.25346.45亿4*ST新潮13.5813.431.19273.38亿6洲际油气 22.8920.341.1 ...
科锐国际收盘下跌6.39%,滚动市盈率29.65倍,总市值65.97亿元
Sou Hu Cai Jing· 2025-08-02 02:46
Group 1 - The core viewpoint of the news is that Keri International's stock has experienced a decline, with a closing price of 33.52 yuan, down 6.39%, and a rolling PE ratio of 29.65 times, indicating a lower valuation compared to the industry average [1] - Keri International's total market capitalization is 6.597 billion yuan, ranking 17th in the professional services industry, which has an average PE ratio of 71.88 times and a median of 41.57 times [1][2] - As of the first quarter of 2025, 34 institutions hold shares in Keri International, with a total of 15.2335 million shares valued at 453 million yuan [1] Group 2 - Keri International specializes in providing comprehensive human resource service solutions, including high-end talent search, recruitment process outsourcing, flexible employment, and technical services [1] - The company has received several awards, including the Best Global Human Resource Service Provider Award for 2024 and recognition as one of Beijing's Top 100 Private Enterprises [1] - In the latest financial report for the first quarter of 2025, Keri International achieved an operating income of 3.303 billion yuan, a year-on-year increase of 25.13%, and a net profit of 57.7839 million yuan, up 42.15%, with a gross profit margin of 5.52% [1]
中曼石油收盘下跌1.59%,滚动市盈率11.35倍,总市值88.86亿元
Sou Hu Cai Jing· 2025-08-01 11:17
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Zhongman Petroleum, indicating a decline in stock price and a relatively low PE ratio compared to industry averages [1][2] - As of August 1, Zhongman Petroleum's stock closed at 19.22 yuan, down 1.59%, with a rolling PE ratio of 11.35 times and a total market capitalization of 8.886 billion yuan [1] - The average PE ratio for the exploration and extraction industry is 29.50 times, with a median of 39.22 times, placing Zhongman Petroleum in 9th position within the industry [1][2] Group 2 - As of March 31, 2025, Zhongman Petroleum had 33,508 shareholders, an increase of 8,199 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business activities of Zhongman Petroleum include exploration and development, oil service engineering, and oil equipment manufacturing, with key products being equipment manufacturing, leasing, drilling engineering services, and oil sales [1] - In the latest quarterly report for Q1 2025, Zhongman Petroleum reported revenue of 943 million yuan, a year-on-year increase of 16.90%, and a net profit of 230 million yuan, up 32.95%, with a gross profit margin of 45.97% [1]